Chiome Bioscience Inc. (JP:4583) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Chiome Bioscience Inc. has initiated a Phase I clinical trial for their novel antibody drug conjugate, ADCT-701, targeting rare neuroendocrine tumors and carcinomas, with the first patient already dosed. The trial, sponsored by the National Cancer Institute, aims to establish the safe dosage and assess the drug’s pharmacokinetics and safety. ADCT-701, which includes Chiome’s cancer therapeutic antibody LIV-1205, is expected to selectively kill cancer cells due to its high efficacy and target selectivity.
For further insights into JP:4583 stock, check out TipRanks’ Stock Analysis page.